^
Association details:
Biomarker:No biomarker
Cancer:Renal Cell Carcinoma
Drug:Proleukin (aldesleukin) (IL-2 stimulant, CD122 agonist)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
07/30/2012
Excerpt:
Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic RCC).